1655 results about "Epitope" patented technology

The invention discloses development, preparation and application of a carbapenemase immunochromatography kit, and belongs to the technical field of biological medicines. According to comparison of amino acid sequences of five common carbapenemase variants of KPC, IMP, NDM, VIM and OXA48 types, the immunogen is prepared from conserved epitope sequences obtained respectively. A mouse is immunized, and a specific antibody pair which is strong in affinity and can be combined with multiple variants is obtained through multi-platform screening. On the basis, the carbapenemase quintuplet detection kit is developed by utilizing an immunochromatography method, has the advantages of high sensitivity, good specificity, capability of covering various drug-resistant variants, capability of detecting multiple targets at one time and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.

The invention discloses an anti-TL1A antibody and a preparation method and application thereof in the technical field of biological medicine. The anti-TL1A antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The antibody provided by the invention has relatively high affinity and better biological activity characterization, and the epitope is different from that of a traditional anti-TL1A antibody.

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.

The invention relates to the technical field of biological medicine, in particular to cat allergen fusion protein, an mRNA immune preparation and application of the cat allergen fusion protein and the mRNA immune preparation. The amino acid sequence of the cat allergen fusion protein disclosed by the invention is as shown in SEQ ID NO.11. The cat allergen fusion protein provided by the invention is a fusion protein obtained by fusing key segments with strong sensitization of Fel d2 and Fel d4 proteins with Fel d1 full-length protein, the fusion protein can simultaneously cover main sensitization epitopes of Fel d1, Fel d2 and Fel d4, and the sensitization effect of cat allergens can be more comprehensively blocked. According to the cat allergen fusion protein provided by the invention, an mRNA immune preparation can be rapidly designed and synthesized, the expression of the cat allergen fusion protein can be accurately controlled in poultry bodies, the immunoreaction is more durable, and the prepared IgY antibody can effectively block allergic protein in cat oral saliva.

The invention discloses preparation and application of an antibody capable of detecting various IMP variants, and belongs to the field of biological medicine. According to the invention, a conserved epitope sequence of IMP enzyme is obtained according to comparison of amino acid sequences of all IMP variants, and an antibody of a spatial epitope is prepared through structural analysis of the epitope. After a mouse is immunized with IMP immunogen protein, hybridoma cells secreting antibodies are obtained through multi-technology platform screening, specific antibody pairs MK35G9 and MK56G2 which are high in affinity and can be combined with multiple IMP variants are obtained after sequencing, and corresponding CDR is obtained through analysis. According to the present invention, the IMP enzyme detection product development is performed based on the immunochromatography platform, such that advantages of high sensitivity, good specificity, covering of a variety of IMP variants, and rapid and convenient detection are provided, and important help is provided for clinical auxiliary diagnosis and medication guidance.

The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule / binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.

The invention provides a specific monoclonal antibody for detecting rotavirus and application of the specific monoclonal antibody, aiming at an epidemic strain of porcine rotavirus, reference to a gene sequence of VP6 protein published by GenBank, antigen epitopes are further optimized, and purified recombinant VP6 protein with antigenicity is obtained for animal immunization. The monoclonal antibody capable of specifically recognizing the porcine rotavirus is successfully screened out. The monoclonal antibody obtained through screening can effectively recognize epidemic strains, has broad-spectrum recognition, is superior to commercially available antibodies, and has high antigen recognition target performance and low non-specificity. And the sequence background is clear, large-scale amplification and production can be carried out, and the method has good commercial value.

The invention provides an anti-human thrombopoietin antibody AF687, a kit and application thereof. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can accurately detect the content of human thrombopoietin in serum, is not influenced by heterogeneity of natural protein glycosylation sites, can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia, and has the advantages that compared with an existing detection reagent, the anti-human thrombopoietin antibody is high in sensitivity and high in sensitivity. The false positive rate can be reduced from 13.9% to 2.7%, and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

The present invention belongs to the field of virus detection technology, and specifically relates to a combination and application of monoclonal antibodies for the specific detection of type 5 adenovirus. The antibody combination includes 8B9 and 4A6, which target different epitopes of the HADV‑5 Hexon protein, respectively, and are suitable for a double-antibody sandwich ELISA detection system. Among them, 8B9 is used as a coating antibody, and 4A6 is used as an HRP-labeled detection antibody. The combination of the two can achieve high sensitivity and high specificity detection of HADV‑5 and replication-deficient recombinant type 5 adenovirus, and does not cross-react with other common adenovirus types. The present invention also provides the variable region amino acid sequence and nucleotide sequence of the above-mentioned antibody, as well as an ELISA detection method based on the antibody combination. The method is simple to operate, has good repeatability, and is suitable for the detection of type 5 adenovirus.

The invention discloses a T cell receptor-epitope binding specificity prediction method based on multilevel knowledge distillation, and relates to a T cell receptor-epitope binding specificity prediction method. The method aims to solve the problem that an existing deep learning model is poor in performance when generalized to be free of epitopes. The feature extraction module is constructed by using the convolutional neural network, and the interaction mode between the TCR and the epitope is explored through a bilinear attention mechanism. Thirdly, internal multi-feature knowledge distillation and inter-domain knowledge distillation are carried out, knowledge is extracted from multiple teacher models, and the predictive ability of student models is enhanced; tCR-epitope pairs in a training set are input into the model, and the model is trained; after multiple iterations, a final prediction model is obtained; and inputting the TCR-epitope pair in the test set into the final prediction model to obtain a prediction result, and performing result analysis. The invention belongs to the technical field of biological information.

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The present invention provide novel immunofiber compositions for protein or peptide purification and simple and cost-efficient methods and systems using these compositions. In some embodiments, the immunofibers comprise a customized Z-33 peptide derived from Staphylococcus aureus Protein A which is used to construct immuno-amphiphile molecules that assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have peptide or protein binding ability.

The invention relates to the field of immunology, and particularly discloses a TCR combination and application thereof, the TCR combination is used for recognizing HBV antigen epitopes, the TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention relates to an in vitro method for detecting a tau protein or fragment thereof in a saliva sample using a specific binding molecule, such as an antibody, directed to key epitopes of tau. The invention may find applications in diagnostics of tauopathies.

The invention provides an antibody combined with an A beta oligomer and application of the antibody, and belongs to the technical field of medicines. The antibody comprises an L chain with CDR1, CDR2 and CDR3, the amino acid sequence of the L chain of the CDR1 is as shown in SEQ ID NO.1, and the amino acid sequence of the L chain of the CDR2 is as shown in SEQ ID NO.2. The amino acid sequence of the L chain of the CDR2 is as shown in SEQ ID NO. 2; the amino acid sequence of the L chain of the CDR3 is as shown in SEQ ID NO.3; an H chain with CDR1, CDR2 and CDR3 is provided, and the amino acid sequence of the H chain of the CDR1 is as shown in SEQ ID NO.4; and ammonia of the H chain of CDR2. The invention provides a monoclonal antibody capable of being combined with an A beta oligomer as well as a preparation method and application of the monoclonal antibody. The monoclonal antibody is used as a raw material, a unique repeated epitope sandwich method is adopted, and high-specificity, high-sensitivity and high-accuracy detection can be carried out on the A beta oligomer.

The invention provides a complementary determining region 3 and immune epitope binding prediction method, and belongs to the field of bioinformatics. According to the method, multi-modal heterogeneous graph modeling, a graph attention network (GAT) and multi-objective loss function collaborative optimization are fused, and the method aims at breaking through the limitation of the prior art in the aspects of heterogeneous data modeling, class imbalance, prediction precision and the like. A heterogeneous graph of 3 nodes of a complementary determining region and immune epitope nodes is constructed, GAT is introduced to realize cross-modal feature interaction, and a dynamic weight optimization strategy of a focus loss function and an AUC loss function is combined, so that the recognition capability and the overall sorting performance of the model on difficult samples are improved. And meanwhile, interpretable analysis combined with the hotspot residues is realized through the attention weight. According to the method, the prediction accuracy of the binding specificity of the complementarity determining region 3 and the immune epitope is remarkably improved, and the method can be widely applied to cancer vaccine design, individualized immunotherapy and autoimmune disease research and has important theoretical significance and practical application value.

The invention provides a humanized monoclonal antibody for detecting a human-synuclein oligomer and application of the humanized monoclonal antibody, and belongs to the technical field of biological engineering. The light chain CDR sequence of the binding part comprises at least one of LCDR1, LCDR2 and LCDR3, and the amino acid sequence of the LCDR1 is as shown in SEQ ID NO: 1; the amino acid sequence of the LCDR2 is as shown in SEQ ID NO: 2, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO: 3. The monoclonal antibody is used as a raw material, and a unique repeated epitope double-antibody sandwich immunodetection method is adopted, so that the human a-Syn oligomer prepared in vitro or in a sample can be detected with high specificity, high sensitivity and high accuracy.

The invention relates to the technical field of biological genetic engineering, in particular to construction of recombinant lactobacillus plantarum of an African swine fever virus antigen, and the method comprises the following steps: constructing a lactobacillus plantarum shuttle vector containing different ASFV antigen genes; and referring to a genome sequence of a Chinese isolate CADCHN09 of ASFV disclosed in GenBank. The method has the advantages that an inducer is not needed, antigen protein is efficiently expressed, the dendritic cell (DC) binding peptide for enhancing immune cell uptake and processing is subjected to fusion expression, the oral immunization mode is simple, mucosal immunity is stimulated, and ASFV infection is effectively prevented and controlled; probiotics, namely lactobacillus plantarum, which naturally exist in animal intestinal tracts and can be colonized and copied in digestive tracts for a long time are used as a carrier; key epitopes of proteins such as nucleocapsid protein p72, outer envelope protein CD2v, inner envelope protein p54, p22, pE199L and pE248R, which play an important role in adsorption, internalization, endocytosis and membrane fusion of ASFV, are preferably fused with dendritic cell binding peptide and then are displayed on the surface of lactobacillus plantarum.

Disclosed herein are predictive models for T-cell epitope prediction, B-cell epitope prediction, and protein design wherein a method is implemented for generating a protein variant amino acid sequence of a target protein having one or more modified properties, the method comprising: (a) iteratively sampling an input amino acid sequence of the target protein, and (b) sampling the individual protein score of at least one weighted relative contribution of the single residue mutant input amino acid sequence to the at least one target property across a plurality of other single residue mutant input amino acid sequences to generate a combined protein score, wherein the combined protein score corresponds to the protein variant comprising one or more amino acid mutations of the single residue mutant input amino acid sequences.

The invention relates to a vaccine for preventing and treating sheep echinococcosis infection and a preparation method thereof.The preparation method comprises the steps that echinococcosis Eg95 full-length gene antigen epitopes are screened through bioinformatics software, screened fragments with high antigenicity are optimized and then subjected to double-copy connection through a flexible linker, His tag sequences are added to the two ends of a tandem sequence, the sequence is as shown in SEQ ID NO.2, and the vaccine for preventing and treating sheep echinococcosis infection is obtained; and the pEE12.4-double Eg95 plasmid is connected with a CHO eukaryotic cell expression vector, so that the pEE12.4-double Eg95 plasmid is obtained. The plasmid is integrated into a CHO eukaryotic cell expression system, the expression quantity of the purified Eg95 protein reaches 10g / L, and a stable and high-yield veterinary vaccine is provided for large-scale production.

The invention discloses a B-cell epitope prediction method, device and equipment based on a protein language model and a computer program product, and the method comprises the steps: respectively inputting a to-be-predicted protein sequence into a pre-trained ESM-IF1 model and a pre-trained ESM2 model to capture a multi-dimensional structure embedding vector and a sequence feature vector, and then carrying out the splicing; the method comprises the following steps: training a multi-dimensional data set through an integrated convolutional neural network based on a Transform architecture, and calculating a TIM loss function; outputting a prediction probability of each amino acid position of the protein sequence by using a deep convolutional neural network model; and if the prediction probability is greater than a set threshold value, determining that the corresponding amino acid position is an epitope, otherwise, determining that the amino acid position is a non-epitope. Vectors output by the protein language model are effectively integrated, the convolutional neural network and Transform are organically fused, deep mining and efficient learning of nonlinear features of the B cell epitopes are achieved, and the method has the advantages of being high in prediction accuracy, high in generalization ability and good in robustness.

The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR); and the Fc region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.

The invention discloses a chemiluminescence heparin binding protein kit and a determination method thereof. The kit comprises reagent components of a reagent R1, a reagent R2 and a reagent R3, as well as a matched calibrator, a matched quality control product, a matched pre-excitation liquid, a matched excitation liquid and a matched cleaning liquid, wherein the reagent R1 contains magnetic particles coated with streptavidin, and the reagent R2 and the reagent R3 are respectively monoclonal antibodies which are labeled by acridinium ester and biotin and are used for recognizing different epitopes of human HBP. The kit shows better sensitivity, wider detection range and high specificity, and can effectively reduce potential endogenous and exogenous interference in clinical samples of potential interference people.

The present application relates to engineered polypeptides wherein the engineered polypeptides comprise an extracellular targeting domain comprising an epitope (e.g., derived from DLL3, PSMA or SSTR2), an extracellular targeting polypeptide spacer domain, and a transmembrane / membrane affinity domain. Methods of using such engineered polypeptides for detecting, imaging, and treating cancer are also described.

The invention belongs to the technical field of biological medicine, particularly relates to an Alzheimer's disease protein marker, an antibody diagnostic kit and application of the antibody diagnostic kit, and provides the Alzheimer's disease protein marker A beta (1-42). The invention provides a kit for detecting human amyloid A beta based on sandwich ELISA (enzyme-linked immunosorbent assay) of 2B6 and 3A8 antibodies, and further provides a kit for detecting human amyloid A beta based on 2B6 and 3A8 antibodies by predicting B cell epitopes of a template A beta (1-42) protein through ABCpred to reconstruct an immune antigen enhanced Alzheimer disease combined antigen such as SEQ ID NO: 1, called AD-A beta 2 for short, and monoclonal antibodies 2B6 and 3A8 with strong affinity and high titer based on the antigen. The A beta concentration detection line effect of at least 0.5 ng / mL is realized.

The invention belongs to the technical field of walnut protein preparation, and particularly relates to walnut protein powder with high digestibility, low sensitization and low bitterness as well as a preparation method and application of the walnut protein powder. According to the preparation method of the walnut protein powder with high digestibility, low sensitization and low bitterness provided by the invention, proline specific endo protease, recombinant trypsin and carboxypeptidase B are cooperatively used, so that accurate damage to an anti-digestion structure and a sensitization epitope of walnut protein can be realized; according to the method, ultrahigh digestibility (greater than or equal to 92%), thorough desensitization (greater than 99.8%), bitterness inhibition and functional peptide enrichment are synchronously realized, so that the defects of low digestibility, sensitization residue, obvious bitterness, low yield of functional peptide, complex process and the like caused by uncontrollable cutting in the existing random enzymolysis technology are overcome, and meanwhile, the core technical bottleneck of high-value utilization of walnut protein is overcome.

The invention relates to the technical field of biological detection, and particularly discloses a one-tube method detection system based on Cas protein modification and application of the one-tube method detection system. An epitope is inserted into the Cas protein, so that the cis-cleavage activity of the Cas protein is weakened. Starting from the Cas protein, the Cas is modified through a protein engineering strategy, the problem of competition between RPA amplification and Cas protein cleavage is successfully solved, and the one-tube method detection system based on Cas protein modification has the characteristics of quick response, high sensitivity, high reliability and simplicity and convenience in operation; and the kit has important practical significance on detection, prevention and treatment of early infection.